Dermatology, Venereology & Andrology Department, Zagazig University Hospitals, Zagazig, Egypt.
Arch Dermatol Res. 2024 Jun 1;316(6):325. doi: 10.1007/s00403-024-03001-4.
Treating plantar warts is still a challenging problem with a long list of diverse treatment options that none of them seems to be definitive. To evaluate the effectiveness of intralesional acyclovir versus intralesional Hepatitis-B vaccine (HBV) in treatment of multiple resistant plantar warts. Forty-eight patients with resistant plantar warts completed the study with no dropouts. They were randomized into 3 groups; group(A) receiving intralesional HBV, group (B) receiving intralesional acyclovir and group (C) receiving intralesional saline as a control group over 5 biweekly sessions or until wart clearance. Clinical outcome was assessed through sequential digital lesion photographing upon each visit. Treatment related adverse reactions were recorded. 43.8%, 37.5% & 18.7% of Groups A, B &C respectively showed a complete response. pain was obvious in 100% and 56.3% of cases receiving intralesional acyclovir and HBV respectively. Up to the 6 month follow up period, none of the complete responders in all groups returned with a recurrence. Both acyclovir and HBV showed comparable efficacy and seem to be promising options for treating plantar warts being safe, affordable, and theoretically safe in immunocompromised cases.
治疗足底疣仍然是一个具有挑战性的问题，有许多不同的治疗选择，但没有一种方法是绝对有效的。评估局部注射阿昔洛韦与局部注射乙型肝炎疫苗（HBV）治疗多种耐药性足底疣的疗效。48 例耐药性足底疣患者完成了研究，无脱落。他们被随机分为 3 组；组（A）接受局部注射 HBV，组（B）接受局部注射阿昔洛韦，组（C）接受局部注射生理盐水作为对照组，共进行 5 次两周一次的治疗，或直到疣清除。通过每次就诊时的连续数字病变照片评估临床结果。记录与治疗相关的不良反应。组 A、B 和 C 的完全缓解率分别为 43.8%、37.5%和 18.7%。接受局部注射阿昔洛韦和 HBV 的病例分别有 100%和 56.3%出现明显疼痛。在 6 个月的随访期内，所有组的完全缓解者均无复发。阿昔洛韦和 HBV 的疗效相当，且对于治疗足底疣是安全、经济且在免疫功能低下的情况下理论上安全的有前途的选择。
